| pubmed-article:11815581 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11815581 | lifeskim:mentions | umls-concept:C0042029 | lld:lifeskim |
| pubmed-article:11815581 | lifeskim:mentions | umls-concept:C0035648 | lld:lifeskim |
| pubmed-article:11815581 | lifeskim:mentions | umls-concept:C0014834 | lld:lifeskim |
| pubmed-article:11815581 | lifeskim:mentions | umls-concept:C0054066 | lld:lifeskim |
| pubmed-article:11815581 | lifeskim:mentions | umls-concept:C0332157 | lld:lifeskim |
| pubmed-article:11815581 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11815581 | pubmed:dateCreated | 2002-1-29 | lld:pubmed |
| pubmed-article:11815581 | pubmed:abstractText | The objective of the study was to define whether individual exposure to co-amoxiclav is a risk factor for selecting co-amoxiclav-resistant Escherichia coli in vivo. One hundred and eight patients were included in our study as soon as they were found to have a urinary tract infection (UTI) due to E. coli. Stool probes were also undertaken for some of these patients. Co-amoxiclav administration in the month before diagnosing the UTI, and any treatment to cure the current UTI were recorded for all patients. When co-amoxiclav-resistant E. coli was detected in the stools after diagnosis of E. coli UTI, isolates were compared with urinary E. coli isolates in terms of clonal relatedness, beta-lactam susceptibility and mechanisms of beta-lactam resistance. The patients who had taken co-amoxiclav in the month before the reported E. coli UTI had a significantly higher risk of being infected with co-amoxiclav-resistant E. coli. Those patients treated with amoxicillin for a current infection were at greater risk of intestinal carriage of co-amoxiclav-resistant E. coli; those treated with co-amoxiclav had a greater risk of intestinal carriage of co-amoxiclav-resistant Gram-negative bacilli than patients treated with third-generation cephalosporins or fluoroquinolones. Hence, individual exposure to co-amoxiclav is a risk factor for UTIs caused by co-amoxiclav-resistant E. coli or for carrying co-amoxiclav-resistant Gram-negative bacilli in the digestive tract. | lld:pubmed |
| pubmed-article:11815581 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11815581 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11815581 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11815581 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11815581 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11815581 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11815581 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:11815581 | pubmed:issn | 0305-7453 | lld:pubmed |
| pubmed-article:11815581 | pubmed:author | pubmed-author:Leflon-Guibou... | lld:pubmed |
| pubmed-article:11815581 | pubmed:author | pubmed-author:TernatGéraldi... | lld:pubmed |
| pubmed-article:11815581 | pubmed:author | pubmed-author:HeymBeateB | lld:pubmed |
| pubmed-article:11815581 | pubmed:author | pubmed-author:Nicolas-Chano... | lld:pubmed |
| pubmed-article:11815581 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11815581 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:11815581 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11815581 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11815581 | pubmed:pagination | 367-71 | lld:pubmed |
| pubmed-article:11815581 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:meshHeading | pubmed-meshheading:11815581... | lld:pubmed |
| pubmed-article:11815581 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11815581 | pubmed:articleTitle | Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection. | lld:pubmed |
| pubmed-article:11815581 | pubmed:affiliation | Microbiology Department, Hôpital Ambroise Paré, AP-HP, and Faculté Paris-Ouest, Université Paris V, France. | lld:pubmed |
| pubmed-article:11815581 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11815581 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11815581 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11815581 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11815581 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11815581 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11815581 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11815581 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11815581 | lld:pubmed |
